Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Videos|June 18, 2015
Shortfalls of Computerized Order Entry Systems
Michael Cohen, RPh, MS, ScD, DPS, FASHP, President of the Institute of Safe Medicine (ISMP) discusses how computerized order entry systems may be a source of medication error.
Advertisement
Michael Cohen, RPh, MS, ScD, DPS, FASHP, President of the Institute of Safe Medicine (ISMP) discusses how computerized order entry systems may be a source of medication error.
This video was shot as ASHP's Summer Meetings and Exposition in Denver in June 2015.
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
5